The abstract is read at the publisher; the summary is JClub's.
Lower pretreatment tumor CD19 expression measured by flow cytometry is linked to worse 1-year progression-free survival after CD19 CAR T-cell therapy in LBCL, with 16% vs 64% for CD19low vs CD19high (P = 0.005).
- Why it matters: It is unclear whether quantitative differences in tumor CD19 meaningfully affect clinical outcomes after CD19-directed CAR-T therapy in large B-cell lymphoma, limiting risk stratification and treatment planning.
- What they did: In an LBCL cohort (n = 301), investigators integrated centralized quantitative tumor CD19 assessment using flow cytometry, immunohistochemistry, and RNA sequencing, and validated transcriptomic associations in an external LBCL cohort (n = 1,017).
- The result: After CAR-T relapse, the fraction of CD19low tumors increased from 17% to 35%, and CD19 locus loss occurred in 8% pre-therapy and 11% post-therapy (P = 0.82), supporting CD19 expression as a clinically meaningful determinant of outcomes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.